ProCE Banner Activity

Phase I CHRYSALIS Update: Amivantamab in Expanded Cohort of Patients With Advanced NSCLC and MET Exon 14 Skipping Mutations

Conference Coverage

An updated analysis of amivantamab at a median follow-up of 10 months showed clinically meaningful antitumor activity in a larger population of patients with METex14-driven metastatic or unresectable NSCLC, with an ORR of 50% in those with treatment-naive disease and an ORR of 21% in those with disease progression after MET inhibitor failure.

Released: September 20, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc